Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 50

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 50
---
, Singapore, Canada, Australia and Israel. Claims are directed to combined uses of IO102, IO103 and anti-PD1 antibody; and  

•Family 15 is based on a PCT application filed February 23, 2023. Patents granted from this family will expire February 23, 2043. The family includes pending applications in the United States, Europe and Japan. Claims are directed to mRNAs encoding all existing candidates in the IO Biotech portfolio, including IO102, IO103 and IO112.  

•IO103 (PD-L1): We own five patent families covering compositions of matter and methods of treatment related to IO103, which were filed between 2012 through 2023. These are Families 2, 3, 13 and 15 listed above, plus Family 4 set out below. Family 5 covers alternative PD-L1 compound IO104.1. 

•Family 4 is based on a PCT application filed October 17, 2012. Patents granted from this family will expire October 17, 2032 based on a normal 20 year term. In the United States, a granted patent covering IO103 as a composition of matter and methods of treatment using IO103 will expire May 11, 2033 due to a patent term adjustment of 206 days. The family includes granted patents in Europe, China, Japan, Brazil and Canada, each of which has claims covering IO103 as a composition of matter and the local equivalent of methods of treatment using IO103. The family also includes pending applications in Europe, Hong Kong and China; and

•Family 5 is based on a PCT application filed June 20, 2017. Patents granted from this family will expire June 20, 2037 based on a normal 20 year term. In the United States, a granted patent covering methods of treatment using IO104.1 will expire June 20, 2037 (no patent term adjustment). In China, a granted patent covering alternative PD-L1 compound IO104.1 as a composition of matter and methods of treatment using IO104.1 will expire August 12, 2037 due to a patent term adjustment of 53 days. In Japan, a granted patent covering IO104.1 as a composition of matter and methods of treatment using IO104.1 will expire June 20, 2037 (no patent term adjustment). The family includes pending applications in the United States and Europe. IO103 is